J.D. Mizrahi, R. Surana, J.W. Valle, R.T. Shroff, Pancreatic cancer. Lancet. 395(10242), 2008–2020 (2020)

Article  CAS  PubMed  Google Scholar 

J.P. Neoptolemos, J. Kleeff, P. Michl, E. Costello, W. Greenhalf, D.H. Palmer, Therapeutic developments in pancreatic cancer: current and future perspectives. Nat. Rev. Gastroenterol. Hepatol. 15(6), 333–348 (2018)

Article  PubMed  Google Scholar 

R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, 2021. CA Cancer J. Clin. 71(1), 7–33 (2021)

Article  PubMed  Google Scholar 

W. Park, A. Chawla, E.M. O’Reilly, Pancreatic cancer: a review. JAMA. 326(9), 851–862 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Mateo, C.J. Lord, V. Serra, A. Tutt, J. Balmaña, M. Castroviejo-Bermejo et al., A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol. 30(9), 1437–1447 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

B. Kaufman, R. Shapira-Frommer, R.K. Schmutzler, M.W. Audeh, M. Friedlander, J. Balmaña et al., Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33(3), 244–250 (2015)

Article  CAS  PubMed  Google Scholar 

M. Robson, S.-A. Im, E. Senkus, B. Xu, S.M. Domchek, N. Masuda et al., Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377(6), 523–533 (2017)

Article  CAS  PubMed  Google Scholar 

K. Moore, N. Colombo, G. Scambia, B.-G. Kim, A. Oaknin, M. Friedlander et al., Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379(26), 2495–2505 (2018)

Article  CAS  PubMed  Google Scholar 

T. Golan, P. Hammel, M. Reni, E. Van Cutsem, T. Macarulla, M.J. Hall et al., Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381(4), 317–327 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

H. Li, Z.Y. Liu, N. Wu, Y.C. Chen, Q. Cheng, J. Wang, PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol. Cancer 19(1), 107 (2020)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.R. Thompson, D. Xu, B.R.G. Williams, ATF3 transcription factor and its emerging roles in immunity and cancer. J. Mol. Med. (Berl) 87(11), 1053–1060 (2009)

Article  CAS  PubMed  Google Scholar 

H. Zhou, N. Li, Y. Yuan, Y.-G. Jin, H. Guo, W. Deng et al., Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target. Basic Res. Cardiol. 113(5), 37 (2018)

Article  PubMed  Google Scholar 

H.-C. Ku, C.-F. Cheng, Master regulator activating transcription factor 3 (ATF3) in metabolic homeostasis and cancer. Front. Endocrinol. (Lausanne). 11, 556 (2020)

Article  PubMed  PubMed Central  Google Scholar 

E.J. Zmuda, L. Qi, M.X. Zhu, R.G. Mirmira, M.R. Montminy, T. Hai, The roles of ATF3, an adaptive-response gene, in high-fat-diet-induced diabetes and pancreatic beta-cell dysfunction. Mol. Endocrinol. 24(7), 1423–1433 (2010)

Article  CAS  PubMed  PubMed Central  Google Scholar 

N. Azizi, J. Toma, M. Martin, M.F. Khalid, F. Mousavi, P.W. Win et al., Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. Oncogene 40(17), 3118–3135 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Kuroda, M. Yamamoto, H. Nagoshi, T. Kobayashi, N. Sasaki, Y. Shimura, et al., Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol. Cancer Res. 8(7), 994–1001 (2010)

S. Borgoni, E. Sofyalı, M. Soleimani, H. Wilhelm, K. Müller-Decker, R. Will, et al., Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer. Cancers. 12(10) (2020)

S.L. Edwards, R. Brough, C.J. Lord, R. Natrajan, R. Vatcheva, D.A. Levine et al., Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182), 1111–1115 (2008)

Article  CAS  PubMed  Google Scholar 

N. Guo, M.Z. Li, L.M. Wang, H.D. Chen, S.S. Song, Z.H. Miao et al., Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. Cancer Biol. Ther. 23(1), 69–82 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A. Wicovsky, F. Henkler, S. Salzmann, P. Scheurich, C. Kneitz, H. Wajant, Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1–TNFR2 cooperation. Oncogene 28(15), 1769–1781 (2009)

Article  CAS  PubMed  Google Scholar 

M.-Q. Du, MALT lymphoma: a paradigm of NF-κB dysregulation. Semin. Cancer Biol. 39, 49–60 (2016)

Article  PubMed  Google Scholar 

S.F. Johnson, C. Cruz, A.K. Greifenberg, S. Dust, D.G. Stover, D. Chi et al., CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 17(9), 2367–2381 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

O. Kondrashova, M. Topp, K. Nesic, E. Lieschke, G.-Y. Ho, M.I. Harrell et al., Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat. Commun. 9(1), 3970 (2018)

Article  PubMed  PubMed Central  Google Scholar 

S. Bandyopadhyay, Y. Wang, R. Zhan, S.K. Pai, M. Watabe, M. Iiizumi et al., The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Can. Res. 66(24), 11983–11990 (2006)

Article  CAS  Google Scholar 

S. Kwok, S.R. Rittling, N.C. Partridge, C.S. Benson, M. Thiyagaraj, N. Srinivasan et al., Transforming growth factor-β1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells. J. Cell. Biochem. 108(2), 408–414 (2009)

Article  CAS  PubMed  Google Scholar 

Y.S. Chang, S.P. Jalgaonkar, J.D. Middleton, T. Hai, Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis. Proc. Natl. Acad. Sci. 114(34), E7159–E7168 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

W. Zhao, M. Sun, S. Li, Z. Chen, D. Geng, Transcription factor ATF3 mediates the radioresistance of breast cancer. J. Cell. Mol. Med. 22(10), 4664–4675 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

D. Fu, C. Wang, L. Yu, R. Yu, Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cell. Mol. Biol. Lett. 26(1), 26 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A.C. Chüeh, J.W.T. Tse, M. Dickinson, P. Ioannidis, L. Jenkins, L. Togel et al., ATF3 repression of BCL-X determines apoptotic sensitivity to HDAC inhibitors across tumor types. Clin. Cancer Res. 23(18), 5573–5584 (2017)

Article  PubMed  PubMed Central  Google Scholar 

Y.H. Jan, H.Y. Tsai, C.J. Yang, M.S. Huang, Y.F. Yang, T.C. Lai et al., Adenylate kinase-4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor ATF3. Can. Res. 72(19), 5119–5129 (2012)

Article  CAS  Google Scholar 

J.-H. Zhu, Q.-L. Yan, J.-W. Wang, Y. Chen, Q.-H. Ye, Z.-J. Wang et al., The key genes for perineural invasion in pancreatic ductal adenocarcinoma identified with Monte-Carlo feature selection method. Front. Genet. 11, 554502 (2020)

Article  CAS